Universal Beteiligungs und Servicegesellschaft mbH Has $23.64 Million Position in Kenvue Inc. $KVUE

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Kenvue Inc. (NYSE:KVUE) by 6.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,129,317 shares of the company’s stock after selling 76,192 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.06% of Kenvue worth $23,637,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Kenvue by 4.9% in the 1st quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the last quarter. Third Point LLC bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $213,422,000. Maverick Capital Ltd. bought a new stake in shares of Kenvue in the 1st quarter valued at approximately $203,036,000. Nuveen LLC acquired a new position in Kenvue in the first quarter worth approximately $187,123,000. Finally, Voya Investment Management LLC raised its position in Kenvue by 131.3% during the first quarter. Voya Investment Management LLC now owns 12,131,468 shares of the company’s stock valued at $290,557,000 after acquiring an additional 6,886,784 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $16.30 on Wednesday. The company has a market capitalization of $31.22 billion, a PE ratio of 21.73, a price-to-earnings-growth ratio of 2.40 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company’s fifty day moving average price is $16.32 and its 200 day moving average price is $19.93.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th will be given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 5.1%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s payout ratio is currently 110.67%.

Analyst Ratings Changes

Several research firms have commented on KVUE. Jefferies Financial Group decreased their target price on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Monday, October 27th. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a report on Tuesday, October 28th. Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. Finally, Deutsche Bank Aktiengesellschaft set a $18.00 price target on Kenvue in a research report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $20.23.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.